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Abstract
Background: Drug use in preterm neonates admitted to Neonatal Intensive Care Unit (NICU) has been investigated, so
far, in terms of unauthorized or off-label use; very little is known on the use of combinations of different active
substances, which is frequently required in this population (prophylaxis of infections, treatment of concomitant diseases).
The aim of this study was to describe the most common patterns of drug use in an Italian NICU, focusing on those with
nephrotoxic potential.
Methods: Medical records of preterm neonates (<37 weeks of gestational age) weighing less than 1,500 g at birth and
admitted to an Italian NICU were scrutinized in a 3-year retrospective investigation. Analysis included drug
exposure, duration of therapies, co-administration of drugs with potential renal side effects; also daily protein
supplement was calculated from parenteral nutrition.
Results: A cohort of 159 preterm neonates was selected; 68 were born weighing less than 1,000 g (extremely low
birth weight infants, ELBW, Group A), 91 weighed between 1,000 and 1,500 g at birth (Group B). Compared to Group B,
neonates of Group A were more likely to receive pharmacological treatments: the most used drugs were antibiotics
(especially ampicillin and amikacin, p = .07 and p < .001, respectively), antifungals (especially fluconazole, p < .001), and
diuretics (especially furosemide, p < .001). Analysis of co-administration of drugs with potential nephrotoxicity showed
ampicillin and amikacin as the most reported combination (94.1% of Group A and 31.9% of Group B), the combination
of furosemide with antibacterials (ampicillin or amikacin) was also frequently reported, with average period of
combination shorter than 2 days.
Conclusions: ELBW infants were exposed to a higher number of drugs compared to other neonates and were more
likely to receive associations of drugs with nephrotoxic potential (e.g. furosemide and amikacin), though only for short
cycles. Further studies should evaluate the safety profile (especially potential renal side effects) related to most commonly
used combinations.
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Background
Neonates, especially those born prematurely, are character-
ized by several specific pathological conditions and require
the administration of several concomitant pharmacological
treatments. For instance, in the first postnatal period,
neonatologists often have to manage respiratory distress
syndrome, patent ductus arteriosus (PDA), necrotizing
enterocolitis (NEC) and other infections [1]. At present,
very little is known on the actual use of combination of
drugs in neonatal intensive care settings and their safety;
studies investigating drug use in the neonatal population
usually focused on single active substances and their status
in terms of unauthorized or off-label use [2–5]. The evi-
dence gathered so far however highlighted increased sus-
ceptibility of babies to drug-related toxicity (especially,
renal damage [2]).
The issue of evidence-based pharmacological treat-
ment among neonates is unsolved, especially because of
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known difficulties in performing clinical trials in this
population. Also observational research by collecting
“real-world” data from Neonatal Intensive Care Units
(NICUs) is challenging because of potential heterogen-
eity of patients enrolled in multicenter studies. Almost
all medications are actually used off-label in newborns
(especially if preterm); some exceptions are represented
by some antibacterials, for instance amikacin. Therefore,
National and Regional guidelines (in Italy, as well as in
most Western Countries, e.g. British National Formulary
for Children) have been created on the basis of consoli-
dated clinical use of off-label drugs in pediatrics, provid-
ing information for neonatal and pediatric units.
Moreover, the Paediatric Committee of the European
Medicines Agency periodically identifies a list of active
substances for which data on efficacy and side effects
in the pediatric population (including neonates) are
requested [6].
Thus, evidence from clinical practice is particularly
useful not only for the assessment of the risk-benefit
profile of drugs in neonates, but also for the opportunity
to add recommendations in this population and to gain
insight into relevant unmet clinical needs.
The present study aims at: (1) describing the use of
drugs among preterm neonates, especially in terms of




The study was conducted retrospectively in the tertiary-
level NICU of the “S. Orsola-Malpighi” Hospital in Bologna
(Northern Italy) after notification to the Institutional Ethics
Committee (Comitato Etico Policlinico S.Orsola-Malpighi,
34/2015/U/Oss). Newborns were included in the study on
the basis of the following criteria: born at the “S.
Orsola-Malpighi” Hospital between January 01, 2009 and
December 31, 2011 and admitted to the NICU of the same
hospital; gestational age < 37 weeks and weight at birth ≤
1,500 g. Patients who died within the first 48 h after
birth were excluded.
Data collection
For each neonate, medical records were scrutinized to col-
lect data on twin birth, pathological conditions at birth
and during the hospitalization, duration of hospitalization,
type of drug prescribed classified according to the ana-
tomical therapeutic chemical (ATC) system (WHO Col-
laborating Centre For Drug Statistics Methodology,
Guidelines for ATC classification and DDD assignment
2009. Oslo, 2008), the starting age and the duration of
therapy. Active substances with potential renal side effects
were identified according to published data [2]: antibacte-
rials (ampicillin, piperacillin, vancomycin, amikacin),
antifungals (amphotericin B), loop diuretics (furosemide),
non-steroidal anti-inflammatory drugs (indomethacin,
ibuprofen), and paracetamol (acetaminophen). All data ac-
quired from medical records were stored in an electronic
database.
Statistical analysis
Neonates were classified into two groups according to
birth weight: Group A neonates weighing ≤ 1,000 g at
birth (extremely low birth weight, ELBW) and Group B
neonates weighing >1,000 g and ≤1,500 g at birth.
Analysis of drug use was performed with Access® soft-
ware and included: (a) exposure, defined as the number
of unique active substances reported for each neonate,
(b) courses, defined as the number of times a unique
active substance was reported for a single patient with a
specific start date (the analysis of courses shows if a
pharmacological treatment was chosen more than once
during hospitalization), (c) courses per exposure (num-
ber of times neonates were exposed to more than one
course of a specific drug) and (d) duration per courses
(when a unique active substance was administered more
than once for a single patient, exposure time for each
course was calculated). Co-administrations of drugs were
calculated on the basis of each neonate daily therapy
and assembling together treatments used in the same
period of time (Fig. 1). For the estimation of protein in-
take, we recorded the daily amount and duration of pro-
tein administration included in the parenteral nutrition.
Differences between groups were evaluated using the
Chi-square test and Fisher’s exact test; statistical signifi-
cance was defined for p ≤ 0.05.
Results
Among all preterm neonates admitted to NICU in
the study period, medical records were available for
159 patients: 68 neonates weighing less than 1,000 g
at birth (Group A), and 91 neonates weighing > 1,000 g




Fig. 1 Schematic representation of our approach to describe
co-administrations of drugs: for instance, when a second drug
was added to drug1, we recorded this exposure as drug1 +
drug2 and considered the relevant co-administration time-period
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and ≤1,500 g (Group B). Characteristics of the two
populations are presented in Table 1. All neonates of
Group A needed pharmacological treatments and they
received a higher number of different active sub-
stances compared to Group B (Table 1): 95,6% of
Group A and 37,4% of Group B received more than
10 different drugs throughout their stay in NICU;
moreover, all ELBW infants and 93,4% of Group B
were exposed to associations.
All neonates of Group A and 93.4% of Group B
were exposed to at least one drug with potential renal
side effect. At birth, all neonates received a single
administration of ophthalmic antibiotic (tobramycin)
and vitamin K; frequency of exposure to drugs, dur-
ation and courses of pharmacological treatments in
both groups are shown in Table 2 and Table 3. In the
first days of life, neonates were especially exposed to
antibacterials, in particular ampicillin and amikacin,
and antifungal agents, mainly fluconazole. In case
another antibacterial was needed after the end of
early treatment with ampicillin or amikacin, the most
prescribed active substances in both groups were
piperacillin, vancomycin, clarithromycin and erythro-
mycin, and they were started on average three weeks
after birth. Neonates weighing less than 1,500 g at
birth were more likely to receive antibacterials (with
the exception of ampicillin) and antifungals compared
to Group B (Table 4); moreover, in neonates of Group
A, treatment with anti-infective agents lasted more
than three times as long as in Group B.
Caffeine was widely used, especially among neonates
of Group A compared to Group B, as well as lung sur-
factants, whose main indications are prevention and
treatment of respiratory distress syndrome; only for few
cases, the additional administration of doxapram was
requested. Neonates of Group A were more likely to
receive diuretics compared to Group B; moreover, neo-
nates of Group A treated with furosemide received at
least two different administrations, with an average
exposure duration of 12 days.
Almost all neonates of Group A were exposed to a
combination of drugs with nephrotoxic potential; the
most commonly reported combination in both groups
was ampicillin and amikacin (94.1% Group A and
31.9% Group B), also the association of furosemide
with ampicillin or amikacin was frequently reported;
the average period of co-administration did not ex-
ceed 2 days, with the exception of piperacillin and
vancomycin in Group B (Table 5). Notably, some of
the investigated combinations, such as ibuprofen with
amikacin, and indomethacin with amikacin, were not
prescribed.
Parenteral nutrition were enriched with proteins in
67/69 cases of Group A and 83/91 cases of Group B; no
significant differences were shown for dosages, whereas
the overall exposure period in Group A was twice as
long as in Group B (Table 6).
Table 1 Characteristics of the study population and
pharmacological treatment
GROUP A GROUP B
N = 68 N = 91
Gesational age, weeks
Average 26 30
Range 22 – 32 27 – 36
Birth weight, g
Average 739 1309
Range 380 – 1000 1023 – 1532
Discharge age, days
Average 57 23
Range 2 – 218 1 – 175






Respiratory distress syndrome 82.4 86.8
Anemia 75.0 35.2
Hyperbilirubinemia 70.6 93.4
Patent ductus arteriosus 52.9 42.9
Sepsis 38.2 11.0
Hyaline membrane disease 27.9 5.5
Intrauterine growth restriction 23.5 17.6
Central nervous system impairment 22.1 8.8
Necrotizing enterocolitis 13.2 5.5
Cardiac malformation 11.8 15.4
Pharmacological treatments, % 100 95.7
Number of drugs, %
≤ 5 0 17.6
5–10 4.4 40.7
11–20 51.5 33.0
> 20 44.1 4.4
Combination of drugs, % 100 93.4
Route of administration, %
Drugs for systemic use 100 96.7
Drugs for topical use 82.4 57.1
Drugs for ophthalmic use 44.1 14.3
Exposure to at least one drug with
potential renal toxicitya, %
100 93.4
GROUP A: birth weight ≤ 1000 g; GROUP B: birth weight >1000 g and ≤1500 g;
aaccording to available data [2]
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Table 2 Most commonly reported active substances in Group A
Active substance Exposure (N = 68) % (tot. 100) Courses Courses/exposure Duration per course, d (average)
Ampicillina 66 97.1 66 - -
Amikacina 66 97.1 76 1.2 6
Caffeine 65 95.6 76 1.2 35
Fluconazole 63 92.6 83 1.3 25
Calcitriol 60 88.2 74 1.2 39
Furosemidea 49 72.1 106 2.2 6
Fentanyl 45 66.2 84 1.9 8
Hydrochlorothiazide 34 50.0 50 1.5 31
Spironolactone 34 50.0 51 1.5 30
Piperacillin and enzyme inhibitora 32 47.1 43 1.3 9
Lung surfactant - natural phospholipids 31 45.6 34 1.1 3
Dopamine 30 44.1 38 1.3 9
Metronidazole 27 39.7 30 1.1 11
Calcium folinate 26 38.2 27 1.0 35
Tobramycin 26 38.2 35 1.3 6
Folic acid 25 36.8 28 1.1 31
Dobutamine 25 36.8 32 1.6 6
Immunoglobulins, normal human, for
intravascular administration
24 35.3 30 1.3 3
Vancomycina 24 35.3 37 1.3 9
Heparinoids for topical use 23 33.8 30 1.5 4
Ibuprofena 22 32.4 22 - -
Ranitidine 21 30.9 22 1.1 24
Filgrastim 21 30.9 26 1.2 1
Clarithromycin 20 29.4 24 1.2 13
Dexamethasone 19 27.9 36 1.9 12
Calcifediol 18 26.5 22 1.2 32
Atropine 17 25.0 19 1.1 1
Albumin 16 23.5 23 1.4 1
Betamethasone 14 20.6 17 1.2 6
Erythromycin ethylsuccinate 13 19.1 13 - -
Lorazepam 12 17.6 23 1.9 1
Doxapram 12 17.6 15 1.3 12
Phytomenadione 11 16.2 13 1.2 17
Oxacillin 11 16.2 13 1.2 8
Paracetamol (Acetaminophen)a 11 16.2 19 1.7 6
Beclometasone 11 16.2 13 1.1 11
Ferrous sulfate 10 14.7 11 1.1 16
Amphotericin Ba 9 13.2 10 1.6 18
Midazolam 9 13.2 14 1.1 10
Insulin (human) 9 13.2 10 1.6 3
Antacids with sodium bicarbonate 7 10.3 11 1.3 4
Glyceryl trinitrate 7 10.3 7 - -
Phenobarbital 6 8.8 6 - -
Girardi et al. Italian Journal of Pediatrics  (2017) 43:37 Page 4 of 9
Discussion
Drug use and combination
In the present study, we described the current medica-
tion use in an Italian NICU and the combination of
drugs: almost all neonates admitted to NICU needed a
combination of drugs, especially ELBW neonates. Com-
bination of drugs with potential nephrotoxicity regarded
antibacterials and furosemide, and their combination did
not exceed 2.5 days.
Most preterm newborns received more than 10 drugs
during their stay in NICU, with large differences be-
tween ELBW and the others. The most commonly used
drugs were antimicrobials, especially ampicillin and ami-
kacin, which were usually co-administered in ELBW for
prophylactic purposes starting from the first postnatal
day. Also furosemide was frequently used, usually start-
ing later, in case of specific cardio-vascular impairment.
For all these three medications, potential nephrotoxicity
is well known. Apart from ampicillin and amikacin, also
combinations with caffeine, used to prevent apnea, and
with fluconazole were frequently found.
The high number of different pharmacological treat-
ments used among preterm neonates in the present in-
vestigation is likely to be related to a dual need: to
preserve vital status of those particularly frail babies
through preventive care therapies, and to treat specific
pathological conditions.
The higher number of drugs received by ELBW is
driven by the fact that these patients are more likely
to suffer from concomitant diseases (especially sepsis)
requiring intensive prophylaxis. Prevention of neonatal
infections is a clinical priority for neonatologists, as
recognized in local protocols, because early and late
onset neonatal sepsis are identified as a major cause
of mortality and are correlated to neurodevelopmental
impairment in the first years of life [7, 8], again espe-
cially in ELBW [9]. In the present study, apart from
the use of specific antimicrobials early after birth, the
use of other antibacterials during hospitalization was
frequent, meaning a high incidence of suspected late-
onset infections (e.g., almost a half of ELBW received
piperacillin). Metronidazole should be separately dis-
cussed because of its main indication in NEC treat-
ment; as a consequence, ELBW patients were more
exposed to metronidazole as they were more likely to
suffer from this pathological condition.
Our results on most used classes of drugs (antimicro-
bials, cardiovascular agents, analgesics and respiratory
drugs) are in accordance to other studies investigating
the profile of drug use in NICUs, performed in other
Western Countries [5, 10–12].
As regards antibiotic choice, our findings are com-
parable to other Italian NICUs [3, 13], but differ from
other Countries [10, 11, 14, 15]. Inter-Country and
inter-centre variability in antibiotic choice, dose regi-
men and intervals in NICUs is commonly reported
worldwide [16–18] and a number of factors may ex-
plain this difference: (a) the lack of clinical trials
performed in this population resulted in deficiency of
international guidelines, (b) clinician’s attitude and
hospital policy may also play an important role in
both the choice of active substances and the pattern
of antibiotic use, (c) moreover, the local epidemiology
of bacterial infection is an essential factor, as well as
previous maternal infections.
While the choice of antibacterial agents is still debated,
the use of fluconazole among newborns as antifungal
prophylaxis is widely acknowledged because of its gen-
eral safety and proven efficacy for the prevention of
invasive candidiasis [19–22].
Drugs with potential renal side effects
Renal damage onset, particularly acute kidney injury, is
common among preterm neonates and correlates with
high mortality rate [23, 24]. Among factors that can
mitigate this risk, the short-term administration of drugs
Table 2 Most commonly reported active substances in Group A (Continued)
Ceftazidime 6 8.8 9 1.5 14
Mupirocin 6 8.8 8 1.3 4
Morphine 5 7.4 7 1.4 20
Hydrocortisone 4 5.9 5 1.3 8
Calcium levofolinate 4 5.9 4 - -
Erythromycin 4 5.9 6 1.5 14
Naloxone 4 5.9 4 - -
Epinephrine 3 4.4 3 - -
Indometacina 3 4.4 3 - -
Epoprostenol 3 4.4 6 2.0 5
Linezolid 3 4.4 3 - -
Birth weight ≤ 1000 g; frequency > 2; adrugs with potential renal side effects [2]
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Table 3 Most commonly reported active substances in Group B
Active substance Exposure (N = 91) % (100) Courses Courses/exposure Duration per course, d (average)
Ampicillina 78 85.7 79 1.0 5
Caffeine 69 75.8 70 1.0 26
Calcitriol 61 67.0 65 1.1 19
Fluconazole 45 49.5 50 1.1 16
Lung surfactant - natural phospholipids 34 37.4 34 - -
Fentanyl 32 35.2 36 1.1 7
Amikacina 32 35.2 33 1.0 4
Calcifediol 25 27.5 27 1.1 18
Furosemidea 23 25.3 32 1.4 8
Atropine 22 24.2 22 - -
Folic acid 16 17.6 18 1.1 11
Calcium folinate 13 14.3 14 1.1 15
Vancomycina 13 14.3 16 1.2 10
Heparinoids for topical use 12 13.2 12 - -
Piperacillin and enzyme inhibitora 11 12.1 13 1.2 10
Dopamine 11 12.1 13 1.2 6
Ibuprofena 11 12.1 11 - -
Filgrastim 10 11.0 11 1.1 1
Tobramycin 9 9.9 10 1.1 4
Ranitidine 8 8.8 10 1.3 21
Immunoglobulins, normal human,
for intravascular administration
8 8.8 8 - -
Hydrochlorothiazide 8 8.8 8 - -
Spironolactone 8 8.8 8 - -
Lorazepam 8 8.8 15 1.9 3
Paracetamol (Acetaminophen)a 7 7.7 12 1.7 4
Metronidazole 7 7.7 8 1.1 8
Ferrous sulfate 7 7.7 7 - -
Piperacillina 7 7.7 7 - -
Doxapram 6 6.6 8 1.3 11
Ceftazidime 6 6.6 8 1.3 11
Mupirocin 6 6.6 6 - -
Alginic acid 6 6.6 8 1.3 12
Glyceryl trinitrate 5 5.5 5 - -
Claritromycin 5 5.5 5 - -
Dobutamine 5 5.5 6 1.2 9
Naloxone 4 4.4 4 - -
Midazolam 4 4.4 5 1.3 5
Betamethasone 3 3.3 6 2.0 11
Phytomenadione 3 3.3 3 - -
Beclometasone 3 3.3 4 1.3 3
Captopril 3 3.3 6 2.0 11
Erythromycin 3 3.3 4 1.3 10
Birth weight >1000 g and ≤1500 g; frequency > 2; adrugs with potential renal side effects [2]
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with nephrotoxic potential, such as aminoglycosides and
diuretics, is recognized [25, 26].
Moreover, recent evidence on aminoglycoside use in
preterm neonates and kidney damage shows that amika-
cin seems to be safer than gentamicin [27].
Our findings on combination of drugs with potential
nephrotoxicity showed that the combinations of two differ-
ent antibacterial agents and an antibacterial with furosem-
ide were frequently reported in preterm neonates, though
for short periods. The benefit-risk profile of combination of
drugs in preterm neonates remains almost unexplored. To
the best of our knowledge, only one study assessed the
clinical consequences of the use of one aminoglycoside and
furosemide in combination in the neonatal intensive care
setting, showing that cycles longer than 4.5 days were asso-
ciated with increased risk of acute kidney injury [28]. In our
population, this combination did not exceed 2 days, thus
minimizing this concern.
Factors that can aggravate kidney damage are prematur-
ity, diet and concomitant disorders, for instance, perinatal
Table 4 Differences between active substances use among groups for the main drug classes





ANTIBACTERIALS FOR SYSTEMIC USE 100,0 91.2 .07 48 14
Ampicillina 97.1 87.5 .07 7 5 .16
Amikacina 97.1 35.2 <.0001 7 4 .33
Piperacillin and enzyme inhibitora 47.1 12.1 <.0001 13 11 .03
Metronidazole 39.7 7.7 <.0001 13 9 .10
Vancomycina 35.3 14.3 <.0001 13 13 .01
Clarithromycin 29.4 5.5 <.0001 15 13 .02
Erythromycin ethylsuccinate 19.1 2.2 <.0001 15 8 .25
ANTIMYCOTICS FOR SYSTEMIC USE 92.6 49.5 <.0001 36 18
Fluconazole 92.6 49.5 <.0001 32 18 .78
Amphotericin Ba 13.2 1.1 .03 20 1 .01
RESPIRATORY SYSTEM PRODUCTS 55.9 39.6 .02 7 3
Lung surfactant - natural phospholipidis 45.6 37.4 .69 3 1 .85
Doxapram 17.6 6.6 .21 15 14 .32
Caffeine 95.6 75.8 .02 45 27 n.a.
DIURETICS 83.8 31.9 <.0001 65 26
Furosemidea 72.1 25.3 .77 12 11 .08
Hydrochlorothiazide 50,0 8.8 .07 46 26 .31
Spironolactone 50,0 8.8 .07 46 26 .31
CARDIAC THERAPY 55.9 28.6 <.0001 23 9
Dopamine 44.1 12.1 .10 12 7 .52
Dobutamine 36.8 5.5 .02 7 11 .02
Ibuprofena 32.4 12.1 .43 2 2 .37
GROUP A: birth weight ≤ 1000 g; GROUP B: birth weight > 1000 g and ≤1500 g; adrugs with potential renal side effects [2]
Table 5 Most commonly reported associations of drugs with potential renal side effects [2]
GROUP A GROUP B
% (N = 68) Duration per course, average % (N = 91) Duration per course, average
Ampicillin, Amikacin 94,1 1,5 31,9 1,4
Piperacillin, Vancomycin 32,4 1,9 9,9 2,5
Amikacin, Furosemide 20,6 1,6 7,7 1,3
Ampicillin, Furosemide 19,1 1,1 15,4 1,6
Amikacin, Acetaminophen 5,9 1,5 2,2 1,2
Amikacin, Amphotericin B 2,9 1,7 - -
GROUP A: birth weight ≤ 1000 g; GROUP B: birth weight >1000 g and ≤1500 g
Girardi et al. Italian Journal of Pediatrics  (2017) 43:37 Page 7 of 9
asphyxia, respiratory distress syndrome and sepsis
[29–32], whereas the effect of protein intake on renal
function in the preterm population is still to be clearly
characterized. Nutritional supply is essential for the
prevention of growth failure of premature babies: in-
sufficient energy and macronutrients intake may lead
to unbalanced growth, altered neurological develop-
ment and increased risk of morbidity [33].
Some limitations of this study should be ackno-
wledged to better interpret our findings: the study
was conducted in a single Italian university hospital,
which may limit the generalizability of our findings to
other settings; also, the amount of protein intake here
described did not take into account enteral nutrition,
resulting in underestimation of the total amount of
protein intake.
Conclusions
With this retrospective study we presented an accur-
ate description of pattern of drug use in an Italian
NICU and, by using a novel approach, we further de-
scribed the combination of active substances. Neo-
nates born prematurely, especially ELBW, received a
number of different pharmacological treatments from
the first day after birth and in several cases drugs were
administered in combination. Most of the drugs used
in combination have potential renal side effects (e.g.
amikacin and ampicillin), but they were administered
for short periods. For most of those drugs, the risk-
benefit profile is still not fully assessed in the neonatal
population, and scanty evidence is available for their
use in combination. Further studies, involving more
than one Centre, should explore the safety of the most
used combinations of drugs in NICU patients, such as
aminoglycosides and furosemide, with special atten-
tion to renal toxicity.
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